In Vivo Efficacy and Toxicity of an Antimicrobial Peptide in a Model of Endotoxin-Induced Pulmonary Inflammation
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24097967 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Laura Cresti und 7 weiteren Autor:innen. Beteiligte Einrichtung: U.O.C. Clinical Pathology, Azienda Ospedaliera Universitaria Senese, Via M. Bracci, 53100 Siena, Italy. Hauptthemen laut MEDLINE: Endotoxins, Pneumonia. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian NRRP, Tuscany Health Ecosystem SPOKE 7, Regione Toscana, Italy, CALL COVID-19, HORIZON-MSCA-2021-DN-01.
Abstract (Originalsprache)
SET-M33 is a synthetic peptide that is being developed as a new antibiotic against major Gram-negative bacteria. Here we report two in vivo studies to assess the toxicity and efficacy of the peptide in a murine model of pulmonary inflammation. First, we present the toxicity study in which SET-M33 was administered to CD-1 mice by snout inhalation exposure for 1 h/day for 7 days at doses of 5 and 20 mg/kg/day. The results showed adverse clinical signs and effects on body weight at the higher dose, as well as some treatment-related histopathology findings (lungs and bronchi, nose/turbinates, larynx and tracheal bifurcation). On this basis, the no observable adverse effect level (NOAEL) was considered to be 5 mg/kg/day. We then report an efficacy study of the peptide in an endotoxin (LPS)-induced pulmonary inflammation model. Intratracheal administration of SET-M33 at 0.5, 2 and 5 mg/kg significantly inhibited BAL neutrophil cell counts after an LPS challenge. A significant reduction in pro-inflammatory cytokines, KC, MIP-1α, IP-10, MCP-1 and TNF-α was also recorded after SET-M33 administration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- U.O.C. Clinical Pathology, Azienda Ospedaliera Universitaria Senese, Via M. Bracci, 53100 Siena, Italy.
- Medical Biotechnology Department, University of Siena, Via A Moro 2, 53100 Siena, Italy.
- SetLance srl, Via Fiorentina 1, 53100 Siena, Italy.
- Zambon spa, Via A. Meucci 3, 20091 Bresso, Italy.
ORCID-Profile: Jlenia Brunetti, Chiara Falciani, Luisa Bracci
Förderung
- Italian NRRP, Tuscany Health Ecosystem SPOKE 7
- Regione Toscana, Italy, CALL COVID-19
- HORIZON-MSCA-2021-DN-01
- collaboration among SetLance srl, Zambon Spa and University of Siena
- Italian NRRP, Tuscany Health Ecosystem SPOKE 7. D.D. n. 1050
Zitieren
APA
Cresti, L., Cappello, G., Vailati, S., Melloni, E., Brunetti, J., Falciani, C., Bracci, L., & Pini, A. (2023). In Vivo Efficacy and Toxicity of an Antimicrobial Peptide in a Model of Endotoxin-Induced Pulmonary Inflammation. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24097967
Vancouver
Cresti L, Cappello G, Vailati S, Melloni E, Brunetti J, Falciani C, et al. In Vivo Efficacy and Toxicity of an Antimicrobial Peptide in a Model of Endotoxin-Induced Pulmonary Inflammation. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24097967
BibTeX
@article{Cresti2023,
author = {Cresti, Laura and Cappello, Giovanni and Vailati, Silvia and Melloni, Elsa and Brunetti, Jlenia and Falciani, Chiara and Bracci, Luisa and Pini, Alessandro},
title = {In Vivo Efficacy and Toxicity of an Antimicrobial Peptide in a Model of Endotoxin-Induced Pulmonary Inflammation},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24097967}
}
EUVIMED